Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to ...
The implant is refillable and about the size of a grain of rice, continuously delivering ranibizumab over a period of months. The need for frequent injections with Lucentis and other wet AMD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results